Study guide

2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data

DABT: Diplomate of the American Board of Toxicology Exam

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Study Design Fundamentals

1.1 Current DABT Exam Facts 1.2 Study Objectives, Hypothesis Testing & Regulatory Guideline Selection 1.3 Test System Selection, Species Models & Animal Welfare (3Rs, IACUC) 1.4 Route Selection, Dosing Regimens & Treatment Duration

2 Dose Selection, Controls & Biostatistics in Toxicology

2.1 Dose Selection Strategies: Range-Finding, Maximum Tolerated Dose (MTD) & Limit Doses 2.2 Control Groups (Negative, Vehicle, Positive, Sham) & Confounding Factors 2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data

3 Study Execution, GLP Compliance & Quality Assurance

3.1 Good Laboratory Practice (GLP) Regulations (FDA 21 CFR Part 58, OECD GLP) & Study Director Responsibilities 3.2 Test Article Characterization, Formulation Analysis, Stability & Homogeneity 3.3 Standard Operating Procedures (SOPs), Quality Assurance Unit (QAU) & Audit Inspections

4 Executing In Vivo, In Vitro, In Silico & Field Studies

4.1 In-Life Clinical Signs, FOB, Body Weight, Food/Water, Ophthalmology 4.2 In Vitro, In Silico (QSAR, Read-Across, PBPK, AI/ML), Field, Clinical & Epidemiologic Characterization

5 Clinical Pathology & Toxicologic Pathology

5.1 Hematology & Coagulation Parameters in Safety Evaluation 5.2 Clinical Chemistry: Biomarkers of Hepatic, Renal & Muscle Injury 5.3 Urinalysis & Specialized Biomarkers of Organ Toxicity 5.4 Toxicologic Pathology: Organ Weights, Gross Necropsy & Histopathology Interpretation

6 Specialized Toxicological Study Endpoints

6.1 Genetic Toxicology Assays: Ames Test, Chromosomal Aberrations & Micronucleus Assays 6.2 Reproductive & Developmental Toxicity Testing (ICH S5, Segments I, II, III) 6.3 Carcinogenicity Bioassays: Design, Conduct & Neoplastic Lesion Evaluation 6.4 Safety Pharmacology (Core Battery: Cardiovascular/hERG, CNS, Respiratory) & Immunotoxicology

7 Toxicokinetics & Biotransformation

7.1 Absorption & Physiological Barriers (Membrane Transport, Blood-Brain Barrier, GI Absorption) 7.2 Distribution, Plasma Protein Binding & Transporters (P-gp, OATs, OCTs, BSEP) 7.3 Phase I Biotransformation: Cytochrome P450 Monooxygenases & Non-CYP Oxidation 7.4 Phase II Biotransformation: Conjugation Pathways, Bioactivation & Detoxification

8 Cellular Mechanisms of Toxicity & Organ Pathogenesis

8.1 Oxidative Stress, Reactive Oxygen/Nitrogen Species (ROS/RNS) & Antioxidant Defenses 8.2 Cell Death Pathways: Necrosis, Apoptosis, Autophagy & Mitochondrial Dysfunction 8.3 Molecular Mechanisms of Target Organ Toxicity: Hepatotoxicity, Nephrotoxicity & Neurotoxicity

9 Hazard Identification & Evidence Integration

9.1 Hazard Identification Principles, Weight of Evidence (WoE) & Systematic Review 9.2 Carcinogen Hazard Classification Schemes (IARC, EPA Guidelines, GHS) 9.3 Agent Classes & Organ-System Toxic Responses

10 Mode of Action, AOPs & Non-Cancer Endpoints

10.1 Mode of Action (MoA) Framework & Human Relevance Evaluation 10.2 Adverse Outcome Pathways (AOP): Molecular Initiating Events, Key Events & Organ-Level Outcomes 10.3 Non-Cancer Systemic Toxicity Endpoints & Target Organ Critical Effects

11 Exposure Assessment Methodologies & Quantification

11.1 Exposure Routes, Scenarios & Pathways (Occupational, Dietary, Environmental, Consumer) 11.2 Exposure Quantification: Dose Equations, Average Daily Dose (ADD) & Lifetime Average Daily Dose (LADD) 11.3 Inhalation Dosimetry: Human Equivalent Concentrations (HEC) & Regional Gas Dose Ratios (RGDR) 11.4 Biomonitoring, Internal Dose, Fate/Transport & BCF

12 Quantitative Dose-Response Principles & Point of Departure Derivation

12.1 Dose-Response Relationships: Threshold vs Non-Threshold, Linear vs Non-Linear Models 12.2 Point of Departure (PoD) Determination: NOAEL, LOAEL & Benchmark Dose (BMD/BMDL) Modeling 12.3 Low-Dose Extrapolation, Cancer Slope Factors (CSF), Unit Risk & First-in-Human Dose

13 Health-Based Guidance Value Derivation & Uncertainty Factors

13.1 Uncertainty Factors (UFs), Interspecies/Intraspecies Extrapolation & Chemical-Specific Adjustment Factors (CSAF) 13.2 Derivation of Reference Values: RfD, RfC, ADI, TDI & Permissible Daily Exposure (PDE)

14 Risk Characterization for Non-Cancer & Cancer Health Effects

14.1 Non-Cancer Risk Characterization: Hazard Quotient (HQ), Hazard Index (HI) & Margin of Exposure (MoE) 14.2 Cancer Risk Characterization: Excess Lifetime Cancer Risk & Acceptable Risk Tolerances 14.3 Uncertainty & Sensitivity Analysis in Risk Characterization

15 Risk Management, Occupational Exposure Limits & Environmental Standards

15.1 Occupational Exposure Limit (OEL) Derivation: OSHA PELs, ACGIH TLVs & NIOSH RELs 15.2 Environmental Quality Standards: Drinking Water MCLs & Air Quality Standards (NAAQS) 15.3 Risk Management Decision-Making, Risk Communication & Socioeconomic Considerations

16 Regulatory Frameworks & Product Stewardship

16.1 Food, Drug & Cosmetic Regulation: FDA Framework, Delaney Clause & GRAS Evaluations 16.2 Chemical Substances & Environmental Regulation: EPA TSCA, FIFRA, Clean Air & Clean Water Acts 16.3 International Regulatory Harmonization: OECD, ICH Guidelines & EU REACH

17 Clinical Toxicology & Medical Management of Poisoning

17.1 Clinical Toxidromes & Initial Management of Acute Poisoning 17.2 Specific Antidotes, Mechanisms of Action & Decontamination Strategies

18 Environmental, Ecological & Public Health Toxicology

18.1 Environmental Toxicology: Fate, Transport, Bioaccumulation (log Kow, BCF) & Ecotoxicological Testing 18.2 Public Health Events, Epidemiology, Susceptible Subpopulations & Exposure Investigation

2.3 Statistical Design, Power Analysis & Statistical Testing of Toxicological Data

Key Takeaways Explain This Topic AI

For control-versus-dose questions on approximately normal, equal-variance data, ANOVA plus Dunnett (each dose versus concurrent control) matches the NOAEL question; Tukey compares every group with every other group and is usually the wrong default.

Non-normal or heterogeneous data typically move to Kruskal–Wallis plus a nonparametric control comparison (for example Steel); ordered dose–response may use Williams, Jonckheere–Terpstra, or Cochran–Armitage trend tests.

Survival is summarized with Kaplan–Meier methods; tumor analysis with differential mortality uses Peto-type fatal-versus-incidental (context-sensitive) tests, not an unadjusted terminal-only chi-square.

OECD TG 408 typically uses 10 animals/sex/group; TG 452 chronic studies normally at least 20/sex; TG 451 carcinogenicity at least 50/sex/group; TG 407’s 5/sex detects only large effects.

A single p < 0.05 ALT in one animal without dose–response, companion enzymes, or histopathology is not automatically a NOAEL-defining adverse effect; large clinical-pathology batteries inflate false positives.

Last updated: September 2026

Domain I.A.1 B (statistical design of studies) and I.C.1 (interpretation of toxicological data) travel together on the DABT exam. One item may show a table of p-values and ask whether the NOAEL should move; another may ask which post-hoc test belongs on a four-group 90-day study. Independent ExamFinch teaching here stays conceptual: match the comparison to the question, respect distributional assumptions, plan for survival and tumors, and do not confuse a lone p < 0.05 with a hazard. This section does not paste software printouts or invented BMDS runs.

Power and sample size

Power is the chance of detecting a true effect of a stated size at a stated alpha. OECD sample sizes are regulatory minima , not a guarantee of 80% power for every endpoint.

  • Study type Typical minimum n (rodents) What that n can and cannot do
  • OECD TG 407 28-day 5/sex/group Large, consistent effects; weak for small clinical-chemistry shifts
  • OECD TG 408 90-day 10/sex/group Core subchronic package; still modest power for rare lesions

OECD TG 452 chronic (usually 12 months) 20/sex/group (4/sex for many non-rodent chronic designs) Better precision than a 90-day; not a lifetime tumor study

OECD TG 451 / 453 carcinogenicity phase 50/sex/group Lifetime tumor detection; still limited for very rare tumors

  • OECD 408 recovery satellite ≥5/sex in control and high dose Reversibility, not a second full 90-day
  • Prenatal developmental (OECD 414) About 20 litters/group Litter is the unit

Conceptually, a two-sample t-test aiming at a 1-standard-deviation mean shift, two-sided α = 0.05, and about 80% power needs on the order of the mid-teens per group . That is why n = 5 (TG 407) is a screen and n = 50 (TG 451) is required for carcinogenicity. OECD TG 451 also notes that a moderate increase above 50 adds relatively little power for rare tumors— dose placement and survival usually buy more interpretability than adding a handful of extra mice. Unequal allocation (more animals at low dose) is sometimes discussed to improve low-dose estimates; it does not rescue a high dose that kills the group by week 8.

The bar chart in this section plots those OECD minima per sex. Recovery satellites and TK extras are additional animals; they are not a substitute for the main-study n that feeds ANOVA and histopathology.

Typical OECD minimum rodents per sex per group

Multiple-group testing: ANOVA, Dunnett, Tukey, and nonparametric cousins

For continuous, approximately normal data with similar variance (body weight, many clinical-chemistry means), the workhorse is one-way ANOVA (or a linear model with sex and dose) followed by a pre-specified post-hoc comparison written into the protocol.

Dunnett’s test compares each dose with the concurrent control . That is the default NOAEL question on a 90-day or chronic study. Multiplicity is built for those control comparisons, not for every pairwise curiosity.

Tukey’s HSD (Tukey–Kramer with unequal n) compares every group with every other group . It spends the error budget on mid-versus-high contrasts that rarely define the NOAEL, and it is more conservative for the control-versus-dose tests you actually need. Use Tukey when there is truly no designated control (several formulations compared with each other).

If a monotonic dose–response is assumed, Williams’ test (or a trend contrast) can be more sensitive at the low end than Dunnett.

If residuals are clearly non-normal or variances are unequal, move the decision tree: Kruskal–Wallis globally, then a nonparametric control comparison ( Steel for control-only; Steel–Dwass for all pairwise). Do not log-transform “until Dunnett looks significant” without a planned rule.

Binary lesion incidence uses other tools: Fisher’s exact or chi-square for two groups, Cochran–Armitage for a dose trend in proportions. Ordered continuous responses may use Jonckheere–Terpstra . Recovery groups that contain only control and former high-dose animals collapse Dunnett to an ordinary two-group comparison (t-test or Wilcoxon) because only two means remain.

Survival and tumors

Kaplan–Meier curves with a log-rank (or Wilcoxon) test compare time to death . They do not, by themselves, analyze tumors.

When mortality differs by dose, raw terminal tumor counts are biased. Animals that die early are not at risk for late-onset incidental tumors found at necropsy, and fatal tumors shorten life. Peto-type (IARC) context-sensitive analysis classifies tumors as fatal versus incidental (and sometimes mortality-independent) and tests a death-rate endpoint for fatal tumors and a prevalence endpoint for incidental tumors, with time on study taken into account. That is the standard long-term bioassay approach—not an unadjusted chi-square on terminal kills only, and not ANOVA on tumor counts as if they were ALT values.

Haseman-type decision rules (different p-value thresholds for common versus rare tumors) appear in NTP interpretation history as a way to manage false positives across many tissues. They are a policy-history point. They do not replace the protocol’s planned statistics or a pathologist’s reading of biological gradient.

Multiplicity, clinical pathology, and statistical versus biological significance

A 90-day study may emit 20–40 clinical-pathology parameters × 2 sexes × 3 doses. At α = 0.05, several “significant” cells are expected by chance. Interpretation uses a pattern , not a single asterisk:

  • Dose–response, both sexes, or a TK reason for one sex
  • Concordant enzymes (ALT and AST, or ALT with GLDH/SDH)
  • Magnitude versus concurrent and matched historical ranges
  • Matching histopathology (hepatocellular necrosis versus glycogen vacuolation)

Statistical significance without that pattern is a hypothesis, not a NOAEL hammer. A clear biological pattern with a p-value that sits near 0.06 is still a toxicologist’s finding.

Protocol scenario. Control male ALT values sit at 35–50 U/L. High-dose males: 38, 41, 44, 47, 49, 52, 55, 58, 61, and one animal at 210 U/L . The group mean is p < 0.05 versus control by Dunnett if the 210 U/L value is kept. Necropsy of that animal shows a handling bruise and no hepatic lesion; the other nine livers are normal; AST, bilirubin, and bile acids are unchanged. Treating 210 U/L as a group liver effect and dropping the NOAEL is poor toxicological reasoning—the signal is one outlier, not a treatment pattern. Conversely, a 30% ALT rise in 8/10 high-dose animals, a parallel AST rise, and centrilobular necrosis in 6/10 is an adverse liver effect even if a reviewer quibbles about exact p-values.

A second scenario on the same 90-day: the statistician, without a protocol amendment, runs Tukey on ALT because “it is stricter.” High versus control is then not significant, but mid versus high is. The NOAEL discussion becomes a pairwise tangle that nobody pre-specified. Re-run the pre-specified Dunnett control comparisons and interpret ALT with the slides.

Bioinformatics and modeling, conceptually

Benchmark-dose (BMD/BMDL) modeling and PBPK models are later interpretation tools in risk assessment. At the study-design stage, know that well-spaced doses , a true low-dose no-effect region, concurrent controls, and adequate n are what those models need. Omics batteries multiply the false-positive problem unless false-discovery control and a hypothesized mechanism are in place. This chapter does not walk through software screens or fabricated output files; the exam tests whether you know why design choices determine whether a model is fittable at all.

Traps

Using Tukey “because it is more rigorous” and then missing a real control-versus-high-dose change. Declaring a NOAEL from p-values without looking at histopathology. Analyzing fetuses as independent n. Ignoring differential survival in a 2-year tumor table. Equating n = 10 (90-day) with n = 50 (carcinogenicity) as if power were identical. Reporting a BMD from a study whose high dose died at week 6.